Bruker Daltonics to Webcast Q4 Conference Call on February 20, 2003.

Business Editors

BILLERICA, Mass.--(BUSINESS WIRE)--Feb. 3, 2003

Bruker Daltonics Inc. (NASDAQ:BDAL) plans to release its fourth quarter financial results on Thursday, February 20, 2003 before the market opens. The company will then host a live streaming-audio CCBN webcast of its operator-assisted earnings conference call at 10:00 a.m. Eastern Time (7:00 a.m. Pacific Time) that same day. To listen to the webcast, investors can go to www.bdal.com, and then click on the live web broadcast symbol. The on-demand webcast will be available through the company web site for 30 days.

Investors can also listen and participate on the telephone in the US and Canada by calling 888-482-0024 or 617-801-9702 outside the US and Canada. Investors should refer to the Bruker Daltonics Fourth Quarter Earnings Call. A telephone replay of the conference call will be available, beginning one hour after the completion of the conference. The replay will be available by dialing toll-free 888-286-8010 in the US and Canada or 617-801-6888 outside the US and Canada, and then entering replay pass code 24684792.

ABOUT BRUKER DALTONICS

Bruker Daltonics is a leading provider of innovative life science tools based on mass spectrometry. Its substantial investment in research and development allows it to design, manufacture and market a broad array of products intended to meet the rapidly growing needs of a diverse customer base, including pharmaceutical companies, biotechnology companies, proteomics companies, molecular diagnostics companies, academic institutions and government agencies. Bruker Daltonics has diverse technology platforms that integrate automated sample preparation and clean-up, advanced front-end AnchorChip(TM) MALDI targets and API source technology with cutting-edge proprietary MALDI-TOF, MALDI-TOF/TOF, ESI-TOF, ESI-Q-q-TOF, ion trap and FTMS mass analyzers, as well as analysis and bioinformatics software. Bruker Daltonics is also a worldwide leader in supplying mass spectrometry-based systems for substance detection and pathogen identification in security, defense and anti-terrorism applications. Further information is available at: www.bdal.com.

CAUTIONARY STATEMENT

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to technological approaches, product development, manufacturing, market acceptance, cost and pricing of Bruker Daltonics' products, dependence on collaborative partners, suppliers, FDA and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation and other risk factors discussed from time to time in Bruker Daltonics' reports or filings with the Securities and Exchange Commission. Bruker Daltonics expressly disclaims any obligation to update the information contained herein.